VCANBIO CELL & GENE ENGINEERING CORP., LTD

Highlights Vcanbio Cell & Gene Engineering Corp., Ltd

Equities

600645

CNE000000545

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-28 pm EDT			5-day change	1st Jan Change
16.97 ^CNY	+3.16%		+8.50%	-16.28%

Apr. 25	Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 25	Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25	CI
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Tranche Update on Vcanbio Cell & Gene Engineering Corp., Ltd's Equity Buyback Plan announced on February 19, 2024.	Apr. 19	CI
Vcanbio Cell & Gene Engineering Corp., Ltd's Equity Buyback announced on February 19, 2024, has closed with 6,181,212 shares, representing 1.32% for CLP 100 million.	Apr. 17	CI
Tranche Update on Vcanbio Cell & Gene Engineering Corp., Ltd's Equity Buyback Plan announced on February 19, 2024.	Apr. 01	CI
Vcanbio Cell & Gene Engineering Corp., Ltd announces an Equity Buyback for CLP 200 million worth of its shares.	Feb. 18	CI
Vcanbio Cell & Gene Engineering Corp., Ltd authorizes a Buyback Plan	Feb. 16	CI
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Vcanbio Cell & Gene Gets Greenlight to Trial COVID-19 Drug	23-10-16	MT
Vcanbio Cell & Gene Engineering Corp., Ltd agreed to acquire additional 3% stake in Heyuan Biological Technology Co., Ltd. from Beijing Fuyuan Zhiyuan Biotechnology Partnership (Limited Partnership).	23-09-28	CI
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
Vcanbio Cell & Gene Unit Gets Nod to Begin Clinical Trial of Respiratory Distress Medication	23-06-08	MT
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-25	CI
Vcanbio Cell & Gene Engineering Wins Nod to Trial Stem Cell Therapy For Liver Cirrhosis	23-02-13	MT
C-Mer Eye Care Raises HK$116.1 Million in Share Subscription Deal	22-12-08	MT
C-Mer Eye Care To Issue More Than 30 Million New Shares to Vcanbio Cell Chairman	22-12-04	MT
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI
Energy firms MET and HH2E to invest in Baltic electrolysis plant	22-06-15	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Vcanbio Cell & Gene Engineering Corp., Ltd

Equities

600645

CNE000000545

Highlights

Filters